Former U.S. CTO: Some health IT firms will push back on My HealthE Data

The My HealthE Data initiative announced by CMS at HIMSS18 earned favorable reactions from health IT professionals at the conference. When it comes to actually allowing patients to access and share their health data, however, some companies which profit from the current “friction-filled health data sharing economy” will resist, according to former U.S. chief technology officer Aneesh Chopra.

Writing for Recode, Chopra said the push announced by CMS would be “fundamental change in the country’s default position when it comes to health data sharing,” though one he favors. There are technical and regulatory challenges—as well as getting patients invested in sharing their data—but he also predicted health IT companies will put up a fight if their bottom lines rely on monetizing patient data.

“Some of those firms will respond in a manner that will violate new rules against 'information blocking,' while others might ​skirt below that threshold while still adding excess transaction fees or threatening developers with intellectual property violations tied to data use,” he wrote.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.